HK1049448B - 用於治療帕金森病的改進的透皮治療系統 - Google Patents

用於治療帕金森病的改進的透皮治療系統

Info

Publication number
HK1049448B
HK1049448B HK03101634.7A HK03101634A HK1049448B HK 1049448 B HK1049448 B HK 1049448B HK 03101634 A HK03101634 A HK 03101634A HK 1049448 B HK1049448 B HK 1049448B
Authority
HK
Hong Kong
Prior art keywords
parkinson
therapeutic system
transdermal therapeutic
disease
treatment
Prior art date
Application number
HK03101634.7A
Other languages
English (en)
Other versions
HK1049448A1 (en
Inventor
Lauterbach Thomas
Wilhelm Schacht Dietrich
Wolff Hans-Michael
Muller Walter
Original Assignee
Ucb Pharma Gmbh
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh, Lts Lohmann Therapie Systeme Ag filed Critical Ucb Pharma Gmbh
Publication of HK1049448A1 publication Critical patent/HK1049448A1/xx
Publication of HK1049448B publication Critical patent/HK1049448B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
HK03101634.7A 2001-05-08 2003-03-05 用於治療帕金森病的改進的透皮治療系統 HK1049448B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111110A EP1256340B1 (en) 2001-05-08 2001-05-08 Improved transdermal therapeutic system for the treatment of Parkinson's disease

Publications (2)

Publication Number Publication Date
HK1049448A1 HK1049448A1 (en) 2003-05-16
HK1049448B true HK1049448B (zh) 2003-12-12

Family

ID=8177357

Family Applications (2)

Application Number Title Priority Date Filing Date
HK03101634.7A HK1049448B (zh) 2001-05-08 2003-03-05 用於治療帕金森病的改進的透皮治療系統
HK04104242.4A HK1061194A1 (en) 2001-05-08 2004-06-11 Improved transdermal therapeutic system for the treatment of parkinson's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK04104242.4A HK1061194A1 (en) 2001-05-08 2004-06-11 Improved transdermal therapeutic system for the treatment of parkinson's disease

Country Status (17)

Country Link
EP (3) EP1256340B1 (zh)
JP (1) JP2004528359A (zh)
KR (1) KR100968293B1 (zh)
CN (1) CN100457095C (zh)
AT (2) ATE246919T1 (zh)
AU (1) AU2002310805B8 (zh)
CY (1) CY1111880T1 (zh)
DE (2) DE60100595T2 (zh)
DK (2) DK1256340T3 (zh)
ES (2) ES2203563T3 (zh)
HK (2) HK1049448B (zh)
HU (1) HU229353B1 (zh)
PT (2) PT1256340E (zh)
RU (1) RU2273477C2 (zh)
SI (1) SI1256340T1 (zh)
WO (1) WO2002089777A1 (zh)
ZA (1) ZA200209980B (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
US8815215B2 (en) † 2003-08-15 2014-08-26 Colgate-Palmolive Company Hydrophobic tooth whitening system and methods of use
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JP2008514376A (ja) * 2004-09-29 2008-05-08 シュウォーツ ファーマ インコーポレイテッド パーキンソン病のための経皮治療システム
US8344165B2 (en) 2007-05-30 2013-01-01 Chemagis Ltd. Crystalline rotigotine base and preparation process therefor
JP5391204B2 (ja) 2007-11-28 2014-01-15 ウーツェーベー ファルマ ゲーエムベーハー ロチゴチンの多形体
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
DE102009052972A1 (de) 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
CA2767068C (en) 2009-12-22 2016-09-27 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
US8729306B2 (en) 2010-02-05 2014-05-20 Ucb Pharma Gmbh Process for the preparation of nitrogen substituted aminotetralins derivatives
CA2798815C (en) 2010-06-25 2017-01-03 Ucb Pharma Gmbh Novel process for the preparation of nitrogen substituted aminotetralins derivatives
CN102475692A (zh) * 2010-11-29 2012-05-30 重庆医药工业研究院有限责任公司 一种防止雷沙吉兰挥发的透皮贴片
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
CN102499906B (zh) * 2011-10-12 2013-04-17 长春健欣生物医药科技开发有限公司 一种罗替戈汀盐酸盐或自由碱成膜凝胶制剂及其制备方法
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
WO2013075822A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system (tts) with rotigotine
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
JP6180520B2 (ja) * 2012-07-05 2017-08-16 エスケー ケミカルス カンパニー リミテッド ロチゴチンを含有した経皮吸収製剤（Ｔｒａｎｓｄｅｒｍａｌｃｏｍｐｏｓｉｔｉｏｎｃｏｍｐｒｉｓｉｎｇｒｏｔｉｇｏｔｉｎｅ）
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
WO2014198422A1 (de) * 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
US10046151B2 (en) 2013-07-03 2018-08-14 Lts Lohmann Therapie-Systeme, Ag Transdermal therapeutic system with electronic component
WO2015177212A1 (en) * 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
JP6895755B2 (ja) 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
ES2924899T3 (es) * 2014-05-20 2022-10-11 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que contiene rotigotina
EP3854388B1 (de) 2020-01-24 2023-10-04 Luye Pharma Switzerland AG Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
JPH0959153A (ja) * 1995-08-18 1997-03-04 Teisan Seiyaku Kk 硝酸イソソルビド含有貼付剤の製造方法
JP3628809B2 (ja) * 1996-06-10 2005-03-16 アルケア株式会社 薬剤徐放性医療用配合物及びその製造方法
JP3615620B2 (ja) * 1996-06-13 2005-02-02 積水化学工業株式会社 貼付剤
WO1999034785A2 (en) * 1998-01-09 1999-07-15 Mor-Research Applications Ltd. Treatment of dyskinesias
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
DK1256339T3 (da) * 2001-05-08 2004-02-09 Sanol Arznei Schwarz Gmbh Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom

Also Published As

Publication number Publication date
SI1256340T1 (en) 2003-12-31
DE60100595T2 (de) 2004-06-24
CY1111880T1 (el) 2015-11-04
DK1256340T3 (da) 2003-12-01
CN100457095C (zh) 2009-02-04
PT1256340E (pt) 2003-12-31
EP1392256B1 (en) 2010-04-21
DK1392256T3 (da) 2010-08-02
AU2002310805B2 (en) 2005-09-08
CN1462185A (zh) 2003-12-17
DE60236078D1 (de) 2010-06-02
ATE464886T1 (de) 2010-05-15
KR20030025941A (ko) 2003-03-29
RU2003128642A (ru) 2005-03-27
WO2002089777A1 (en) 2002-11-14
JP2004528359A (ja) 2004-09-16
HUP0302897A2 (hu) 2003-12-29
HUP0302897A3 (en) 2005-02-28
EP1392256A1 (en) 2004-03-03
ES2344782T3 (es) 2010-09-07
ES2203563T3 (es) 2004-04-16
ATE246919T1 (de) 2003-08-15
PT1392256E (pt) 2010-07-13
EP1325742A1 (en) 2003-07-09
ZA200209980B (en) 2003-02-24
HK1049448A1 (en) 2003-05-16
DE60100595D1 (de) 2003-09-18
AU2002310805B8 (en) 2006-01-12
HU229353B1 (en) 2013-11-28
HK1061194A1 (en) 2004-09-10
KR100968293B1 (ko) 2010-07-07
RU2273477C2 (ru) 2006-04-10
EP1256340B1 (en) 2003-08-13
EP1256340A1 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
HK1061194A1 (en) Improved transdermal therapeutic system for the treatment of parkinson's disease
DE60100994D1 (de) Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
DK1623703T3 (da) Hydrocodonformuleringer med kontrolleret frigivelse
HUP0401568A2 (hu) Periokuláris vagy subconjunctivális adagolásra alkalmas szemészeti depó készítmények
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
HUP0100437A2 (hu) Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
DK1265629T3 (da) Anvendelse af væksthormon i lav dosis

Legal Events

Date Code Title Description
PF Patent in force